Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses

Fast gapped-read alignment with Bowtie 2

Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · see citing works

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

REVIGO summarizes and visualizes long lists of gene ontology terms

Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264 · see citing works

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · see citing works

Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEMPreprint

Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 5,150 · see citing works

CellProfiler: image analysis software for identifying and quantifying cell phenotypes

Carpenter, A. E., Jones, T. R., Lamprecht, M. R., Clarke, C., Kang, I. H., Friman, O., Guertin, D. A., Chang, J. H., Lindquist, R. A., Moffat, J., et al. (2006) · Genome biology · doi:10.1186/gb-2006-7-10-r100 · Cited by 5,077 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works

<i>Batf3</i> Deficiency Reveals a Critical Role for CD8α ⁺ Dendritic Cells in Cytotoxic T Cell Immunity

Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · see citing works

Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · see citing works

Fractional Photothermolysis: A New Concept for Cutaneous Remodeling Using Microscopic Patterns of Thermal Injury

Manstein, D., Herron, G. S., Sink, R. K., Tanner, H., & Anderson, R. R. (2004) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20048 · Cited by 1,605 · see citing works

Mouse genomic variation and its effect on phenotypes and gene regulation.

Keane, T. M., Goodstadt, L., Danecek, P., White, M. A., Wong, K., Yalcin, B., Heger, A., Agam, A., Slater, G., Goodson, M., et al. (2011) · Nature · doi:10.1038/nature10413 · Cited by 1,580 · see citing works

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207 · see citing works

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells

Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192 · see citing works

BrafV600E cooperates with Pten loss to induce metastatic melanoma

Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189 · see citing works

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081 · see citing works

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0654-5 · Cited by 1,039 · see citing works

A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells

Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 934 · see citing works

Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells

Edelson, B. T., Wumesh, K. C., Juang, R., Kohyama, M., Benoît, L. A., Klekotka, P. A., Moon, C., Albring, J. C., Ise, W., Michael, D. G., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091627 · Cited by 710 · see citing works

Central role of p53 in the suntan response and pathologic hyperpigmentation

Cui, R., Widlund, H. R., Feige, E., Lin, J. Y., Wilensky, D. L., Igras, V. E., D'Orazio, J., Fung, C. Y., Schanbacher, C. F., Granter, S. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.045 · Cited by 657 · see citing works

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655 · see citing works

Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients

van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A. M., van der Veen, J. P. W., Bos, J. D., Melief, C. J. M., Vyth‐Dreese, F. A., & Luiten, R. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.32 · Cited by 542 · see citing works

Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

Rodig, N., Ryan, T., Allen, J. A., Pang, H. B., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 493 · see citing works

The melanoma revolution: From UV carcinogenesis to a new era in therapeutics

Lo, J. A., & Fisher, D. E. (2014) · Science · doi:10.1126/science.1253735 · Cited by 426 · see citing works

Improving Melanoma Classification by Integrating Genetic and Morphologic Features

Virós, A., Fridlyand, J., Bauer, J. M., Lasithiotakis, K., Garbe, C., Pinkel, D., & Bastian, B. C. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050120 · Cited by 376 · see citing works

Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256 · see citing works

<scp>UV</scp>‐induced somatic mutations elicit a functional T cell response in the <scp>YUMMER</scp>1.7 mouse melanoma model

Wang, J., Perry, C. J., Meeth, K., Thakral, D., Damsky, W., Micevic, G., Kaech, S., Blenman, K., & Bosenberg, M. (2017) · Pigment Cell &amp; Melanoma Research · doi:10.1111/pcmr.12591 · Cited by 199 · see citing works

Roles of inflammation factors in melanogenesis (Review)

Fu, C., Chen, J., Lu, J., Lu, Y., Tong, X., Kang, L., Pei, S., Ouyang, Y., Jiang, L., Ding, Y., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10950 · Cited by 168 · see citing works

Treatment of lentigo maligna with topical imiquimod

Naylor, M. F., Crowson, N., Kuwahara, R. T., Teague, T. K., García, C., Mackinnis, C., Haque, R., Odom, C., Jankey, C., & Cornelison, R. L. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05637.x · Cited by 165 · see citing works

The influence of the hair cycle on the thickness of mouse skin

Hansen, L. S., Coggle, J. E., Wells, J., & Charles, M. W. (1984) · The Anatomical Record · doi:10.1002/ar.1092100404 · Cited by 150 · see citing works

Multiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032

Jenkins, M. H., Steinberg, S. M., Alexander, M. P., Fisher, J. L., Ernstoff, M. S., Turk, M. J., Mullins, D. W., & Brinckerhoff, C. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12220 · Cited by 86 · see citing works

Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type

Swetter, S. M., Chen, F. W., Kim, D. D., & Egbert, B. M. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.008 · Cited by 75 · see citing works

Data mining The Cancer Genome Atlas in the era of precision cancer medicine

Cheng, P. F., Dummer, R., & Levesque, M. P. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14183 · Cited by 61 · see citing works

Fractional laser exposure induces neutrophil infiltration (N1 phenotype) into the tumor and stimulates systemic anti-tumor immune response

Kawakubo, M., Demehri, S., & Manstein, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184852 · Cited by 21 · see citing works

Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity

Kuehm, L. M., Wolf, K. J., Zahour, J., DiPaolo, R. J., & Teague, R. M. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02346-4 · Cited by 9 · see citing works

Identification of neoantigens for individualized therapeutic cancer vaccines

Lang, F., Schrörs, B., Löwer, M., Türeci, Ö., & Şahin, U. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00387-y · Cited by 553 · see citing works

Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities

Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 534 · see citing works

Anatomically distinct fibroblast subsets determine skin autoimmune patterns

Xu, Z., Chen, D., Hu, Y., Jiang, K., Huang, H., Du, Y., Wu, W., Wang, J., Sui, J., Wang, W., et al. (2021) · Nature · doi:10.1038/s41586-021-04221-8 · Cited by 308 · see citing works

Cancer immune evasion, immunoediting and intratumour heterogeneity

Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 286 · see citing works

Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity

Collier, J. L., Weiss, S. A., Pauken, K. E., Sen, D. R., & Sharpe, A. H. (2021) · Nature Immunology · doi:10.1038/s41590-021-00949-7 · Cited by 237 · see citing works

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants

Bhagchandani, S. H., Johnson, J. A., & Irvine, D. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.013 · Cited by 193 · see citing works

The Role of Viral Infections in the Onset of Autoimmune Diseases

Sundaresan, B., Shirafkan, F., Ripperger, K., & Rattay, K. (2023) · Viruses · doi:10.3390/v15030782 · Cited by 194 · see citing works

Targeting TBK1 to overcome resistance to cancer immunotherapy

Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05704-6 · Cited by 174 · see citing works

Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth

Zhao, H., Teng, D., Yang, L., Xu, X., Chen, J., Jiang, T., Feng, A. Y., Zhang, Y., Frederick, D. T., Gu, L., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00676-9 · Cited by 173 · see citing works

Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma

Molodtsov, A. K., Khatwani, N., Vella, J. L., Lewis, K. A., Zhao, Y., Han, J., Sullivan, D. E., Searles, T. G., Preiss, N. K., Shabaneh, T. B., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.019 · Cited by 155 · see citing works

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 116 · see citing works

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells

Wang, K., Coutifaris, P., Brocks, D., Wang, G., Azar, T., Solis, S., Nandi, A., Anderson, S., Han, N. A., Manne, S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.007 · Cited by 120 · see citing works

Effects of immune‐related adverse events ( irAEs ) and their treatment on antitumor immune responses

Blum, S. M., Rouhani, S. J., & Sullivan, R. J. (2023) · Immunological Reviews · doi:10.1111/imr.13262 · Cited by 103 · see citing works

Patho-immunological mechanisms of vitiligo: The role of the innate and adaptive immunities and environmental stress factors

Faraj, S., Kemp, E. H., & Gawkrodger, D. J. (2022) · Clinical and Experimental Immunology · doi:10.1093/cei/uxab002 · Cited by 94 · see citing works

Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity

Liu, L., Chen, J., Zhang, H., Ye, J., Moore, C., Lu, C., Fang, Y., Fu, Y., & Li, B. (2022) · Nature Cancer · doi:10.1038/s43018-022-00352-7 · Cited by 84 · see citing works

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study

Zhang, S., Tang, K., Wan, G., Nguyen, N., Lu, C., Ugwu‐Dike, P., Raval, N. S., Seo, J., Alexander, N. A., Jairath, R., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.12.048 · Cited by 83 · see citing works

Molecular patterns of resistance to immune checkpoint blockade in melanoma

Lauss, M., Phung, B., Borch, T. H., Harbst, K., Kaminska, K. K., Ebbesson, A., Hedenfalk, I. A., Yuan, J., Nielsen, K., Ingvar, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47425-y · Cited by 85 · see citing works

Redefining FLASH RT: the impact of mean dose rate and dose per pulse in the gastrointestinal tract

Liu, K., Waldrop, T., Aguilar, E. A., Mims, N., Neill, D. W., Delahoussaye, A. M., Li, Z., Swanson, D., Lin, S. H., Koong, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.10.009 · Cited by 62 · see citing works

SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 Axis

Yokoyama, S., Takahashi, A., Kikuchi, R., Nishibu, S., Lo, J. A., Hejna, M., Moon, W. M., Kato, S., Zhou, Y., Hodi, F. S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2078 · Cited by 62 · see citing works

Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy

Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 57 · see citing works

Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors

Rivero-Hinojosa, S., Grant, M., Panigrahi, A. K., Zhang, H., Caisová, V., Bollard, C. M., & Rood, B. R. (2021) · Nature Communications · doi:10.1038/s41467-021-26936-y · Cited by 52 · see citing works

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

López, L., Morosi, L. G., Terza, F. L., Bourdely, P., Rospo, G., Amadio, R., Piperno, G. M., Russo, V., Volponi, C., Vodret, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46685-y · Cited by 52 · see citing works

Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs

Zhao, J., Ye, H., Qi, L., Wang, K., Chen, X., Song, J., Wang, H., Lu, Y., Cheng, M., He, Z., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01270-7 · Cited by 51 · see citing works

Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion

Lommerts, J. E., Bekkenk, M. W., & Luiten, R. M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1915279 · Cited by 50 · see citing works

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Lubrano, S., Cervantes‐Villagrana, R. D., Faraji, F., Ramirez, S. I., Sato, K., Adame-Garcia, S. R., Officer, A., Arang, N., Rigiracciolo, D. C., Quiroz, P. Y. A., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.001 · Cited by 49 · see citing works

Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer

Apavaloaei, A., Zhao, Q., Hesnard, L., Cahuzac, M., Durette, C., Larouche, J., Hardy, M., Vincent, K., Brochu, S., Laverdure, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00979-2 · Cited by 45 · see citing works

Nitric Oxide‐Based Nanomedicines for Conquering TME Fortress: Say “NO” to Insufficient Tumor Treatment

Xiang, Y., Chen, Q., Nan, Y., Liu, M., Xiao, Z., Yang, Y., Zhang, J., Ying, X., Long, X., Wang, S., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202312092 · Cited by 44 · see citing works

Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

Berner, F., Bomze, D., Lichtensteiger, C., Walter, V. P., Niederer, R., Ali, O. H., Wyss, N., Bauer, J., Freudenmann, L. K., Marcu, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn9644 · Cited by 40 · see citing works

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia

Nelde, A., Maringer, Y., Bilich, T., Salih, H. R., Roerden, M., Heitmann, J. S., Marcu, A., Bauer, J., Neidert, M. C., Denzlinger, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705974 · Cited by 37 · see citing works

Learning from the nexus of autoimmunity and cancer

Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33 · see citing works

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

Dousset, L., Pacaud, A., Barnetche, T., Kostine, M., Dutriaux, C., Pham‐Ledard, A., Beylot-Barry, M., Gerard, É., Prey, S., Andreu, N., et al. (2021) · JAAD International · doi:10.1016/j.jdin.2021.09.002 · Cited by 32 · see citing works

A mouse model of vitiligo based on endogenous auto-reactive CD8 + T cell targeting skin melanocyte

Chen, D., Xu, Z., Cui, J. X., & Chen, T. (2022) · Cell Regeneration · doi:10.1186/s13619-022-00132-9 · Cited by 31 · see citing works

Breast cancer immunopeptidomes contain numerous shared tumor antigens

Kina, E., Laverdure, J., Durette, C., Lanoix, J., Courcelles, M., Zhao, Q., Apavaloaei, A., Larouche, J., Hardy, M., Vincent, K., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166740 · Cited by 31 · see citing works

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma

Borch, T. H., Harbst, K., Rana, A. H., Andersen, R. S., Martinenaite, E., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J. W., Kverneland, A. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002703 · Cited by 28 · see citing works

Raptinal Induces Gasdermin E–Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma

Vernon, M., Wilski, N. A., Kotas, D., Cai, W., Pomante, D., Tiago, M., Alnemri, E. S., & Aplin, A. E. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0040 · Cited by 28 · see citing works

Antigen transfer and its effect on vaccine-induced immune amplification and tolerance

Shi, Y., Lu, Y., & You, J. (2022) · Theranostics · doi:10.7150/thno.75904 · Cited by 27 · see citing works

Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges

Dara, L., & Martin, E. D. (2025) · Liver International · doi:10.1111/liv.16198 · Cited by 25 · see citing works

DHODH modulates immune evasion of cancer cells via CDP-Choline dependent regulation of phospholipid metabolism and ferroptosis

Teng, D., Swanson, K. D., Wang, R., Zhuang, A., Wu, H., Niu, Z., Cai, L., Avritt, F. R., Gu, L., Asara, J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59307-y · Cited by 24 · see citing works

Lung injury induces a polarized immune response by self-antigen-specific CD4+ Foxp3+ regulatory T cells

Shin, D. S., Ratnapriya, S., Cashin, C. N., Kuhn, L. F., Rahimi, R. A., Anthony, R. M., & Moon, J. J. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112839 · Cited by 22 · see citing works

CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success

Ludin, A., Stirtz, G. L., Tal, A., Nirmal, A. J., Pfaff, K. L., Manos, M. P., Besson, N. R., Eskndir, N., Porter, B. A., Jones, S. M., et al. (2025) · Cell · doi:10.1016/j.cell.2025.09.021 · Cited by 22 · see citing works

A dual-adjuvant neoantigen nanovaccine loaded with imiquimod and magnesium enhances anti-tumor immune responses of melanoma

Chen, X., Cen, L., Liu, Q., Chu, Y., Feng, X., Ke, Y., Zhang, Z., Dai, H., Huang, S., Liu, B., et al. (2022) · Biomaterials Science · doi:10.1039/d2bm01340a · Cited by 19 · see citing works

Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function

Ifejeokwu, O. V., Do, A. H., El-Khatib, S. M., Ho, N., Zavala, A., Othy, S., & Acharya, M. M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03442-3 · Cited by 20 · see citing works

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins

Fessenden, T. B., Stopfer, L. E., Chatterjee, F., Zulueta, J., Mesfin, J. M., Dumit, T. C., Reijers, I. L. M., Hoefsmit, E. P., Blank, C. U., White, F. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004159 · Cited by 16 · see citing works

T cell help in the autoreactive germinal center

Akama‐Garren, E. H., & Carroll, M. C. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13192 · Cited by 16 · see citing works

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

Attias, M., & Piccirillo, C. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16313 · Cited by 19 · see citing works

The Identification of the Metabolism Subtypes of Skin Cutaneous Melanoma Associated With the Tumor Microenvironment and the Immunotherapy

Yang, R., Wang, Z., Li, J., Pi, X., Gao, R., Ma, J., Qing, Y., & Zhou, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707677 · Cited by 16 · see citing works

Advances in Vaccines for Melanoma

Cui, C., Ott, P. A., & Wu, C. J. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.009 · Cited by 16 · see citing works

Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study

Wan, G., Khattab, S., Leung, B. W., Zhang, S., Nguyen, N., Tran, M., Lin, C., Chang, C. T., Alexander, N., Jairath, R., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae053 · Cited by 14 · see citing works

Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity

Zhang, X., Halberstam, A. A., Zhu, W., Leitner, B. P., Thakral, D., Bosenberg, M., & Perry, R. J. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00296-7 · Cited by 13 · see citing works

Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser

Omland, S. H., Ejlertsen, J. S., Krustrup, D., Christensen, R. L., Svane, I. M., Olesen, U. H., & Hædersdal, M. (2022) · Cancers · doi:10.3390/cancers14235815 · Cited by 12 · see citing works

Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy

Menzel, L., Zhou, H., Baish, J. W., O’Melia, M. J., Darragh, L. B., Effiom, D. N., Specht, E., Czapla, J., Lei, P., Rajotte, J. J., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.09.009 · Cited by 13 · see citing works

Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors

Azin, M., Farokh, P., McGarry, A., Leung, B. W., Roster, K., Rashdan, H., Rajeh, A. A., Khattab, S., Stephens, M., Thang, C. J., et al. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.08.008 · Cited by 11 · see citing works

HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion

Chemla, Y., Itzhaki, O., Melamed, S., Weller, C., Sade, Y., Manich, P., Reshef, K., Xenidis, N., Maliah, A., Levy, G., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.020 · Cited by 11 · see citing works

Activated B-Cells enhance epitope spreading to support successful cancer immunotherapy

Kellermann, G., Leulliot, N., Cherfils‐Vicini, J., Blaud, M., & Brest, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382236 · Cited by 10 · see citing works

Targeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma

Khorsandi, S., Huntoon, K. M., Wang, Y., Woodward, A., Antony, A., Endsley, C., Hafeez, N., Edwards, J. L., Guenthner, N., Alluri, P. G., et al. (2025) · Advanced Science · doi:10.1002/advs.202416596 · Cited by 10 · see citing works

Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma

Omland, S. H., Wenande, E. C., Svane, I. M., Tam, J., Olesen, U. H., & Hædersdal, M. (2021) · Cancers · doi:10.3390/cancers13215405 · Cited by 10 · see citing works

A nano-enhanced vaccine for metastatic melanoma immunotherapy

Salotto, K. E., Olson, W. C., Pollack, K. E., Illendula, A., Michel, E., Henriques, S., Fox, T. E., Walker, S., Dunlap-Brown, M. E., Slingluff, C. L., et al. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.132 · Cited by 9 · see citing works

Exosomes enriched with miR-31-3p from keratinocytes under oxidative stress promote vitiligo progression by destructing melanocytes and activating CD8+ T cells

Ma, J., Zhou, Y., Chen, J., Guo, S., Zhang, W., Yi, X., Du, P., Wang, Y., Chen, J., Li, S., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143070 · Cited by 9 · see citing works

Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment

Huang, M., Xia, Y., Li, K., Shao, F., Feng, Z., Li, T., Azin, M., & Demehri, S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166494 · Cited by 9 · see citing works

1,25-Dihydroxyvitamin D3 Provides Benefits in Vitiligo Based on Modulation of CD8+ T Cell Glycolysis and Function

Wei, Y., Wang, T., Nie, X., Shi, Z., Liu, Z., Zeng, Y., Pan, R., Zhang, R., Deng, Y., & Li, D. (2023) · Nutrients · doi:10.3390/nu15214697 · Cited by 8 · see citing works

The many faces of autoimmune-mediated melanocyte destruction in melanoma

Ungureanu, L., Vasilovici, A. F., Halmágyi, S.-R., Trufin, I. I., Apostu, A. P., & Șenilă, S. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1417273 · Cited by 8 · see citing works

Epitope Spreading and the Efficacy of Immune Checkpoint Inhibition in Cancer

Robert, L. W., & Fisher, D. E. (2021) · International Journal of Oncology Research · doi:10.23937/2643-4563/1710029 · Cited by 8 · see citing works

Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy

Kubo, T., Shinkawa, T., Kikuchi, Y., Murata, K., Kanaseki, T., Tsukahara, T., Hirohashi, Y., & Torigoe, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679095 · Cited by 8 · see citing works

Anti-PD-1 Therapy with Adjuvant Ablative Fractional Laser Improves Anti-Tumor Response in Basal Cell Carcinomas

Olesen, U. H., Wiinberg, M., Lerche, C. M., Jæhger, D. E., Andresen, T. L., & Hædersdal, M. (2021) · Cancers · doi:10.3390/cancers13246326 · Cited by 8 · see citing works

Prognostic biomarkers for survival in mucosal melanoma

Thierauf, J., Kaluziak, S. T., Codd, E. M., Dybel, S. N., Jobbagy, S., Purohit, R., Farahani, A. A., Dedeilia, A., Naranbhai, V., Hoang, M. P., et al. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13104 · Cited by 7 · see citing works

Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Wang, Y., Hu, M., Finn, O. J., & Wang, X. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0932 · Cited by 7 · see citing works

Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade

Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 6 · see citing works

Enhanced Antitumor Response to Immune Checkpoint Blockade Exerted by Cisplatin-Induced Mutagenesis in a Murine Melanoma Model

Gorgun, F. M., Widen, S. G., Tyler, D. S., & Englander, E. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701968 · Cited by 6 · see citing works

Innovative dual-contrast nanocoating for central venous catheters: prolonged infection resistance and enhanced imaging

Golroudbari, H. T., Mojtabavi, S., Mohammadi, M., Dehpour, A. R., Tafti, S. H. A., Tafti, S. M. A., & Faramarzi, M. A. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02461c · Cited by 5 · see citing works

Immune checkpoint inhibitor‐induced vitiligo: A large‐scale real world pharmacovigilance study

Tang, B., Yu, Y., Wan, J., Yu, C., Sun, Y., Yu, X., Liu, R., Huang, H., Du, Y., Hu, W., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70159 · Cited by 5 · see citing works

Abscopal Effects and Immunomodulation in Skin Cancer Therapy

Nahm, W. J., Sakunchotpanit, G., & Nambudiri, V. E. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00943-x · Cited by 5 · see citing works

Cancer Risk in Vitiligo: No Evidence of Increased Prevalence—A Systematic Review and Meta-analysis

Mohammed, A. A., Lengyel, A., Meznerics, F. A., Szondy, I., Walter, A., Nagy, B., Csábi, Z. E., Bánvölgyi, A., Kiss, N., Hegyi, P., et al. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01520-0 · Cited by 4 · see citing works

Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity

Jiménez-Andrade, Y., Flesher, J. L., & Park, J. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.002 · Cited by 4 · see citing works

Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort study

Rashdan, H., Zhang, S., Wan, G., Nguyen, N., Roster, K., Rajeh, A. A., Tang, K., Chen, W., Moseley, C., Chen, S., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.01.038 · Cited by 4 · see citing works

Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation

Silvestrini, A. V. P., Lucas, J. M., Cardoso, C. R. D. B., & Bentley, M. V. L. B. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09165-3 · Cited by 3 · see citing works

Association Between Immune‐Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study

Yamamoto, K., Hirano, H., Hirose, T., Shoji, H., Okita, N. T., Takashima, A., & Kato, K. (2025) · Cancer Medicine · doi:10.1002/cam4.71252 · Cited by 3 · see citing works

Immune Checkpoint Inhibition-related Neuroinflammation Disrupts Cognitive FunctionPreprint

Ifejeokwu, O. V., Do, A., El-Khatib, S. M., Ho, N., Zavala, A., Othy, S., & Acharya, M. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.01.601087 · Cited by 3 · see citing works

Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade

Guerrieri, R. A., Fischer, G. M., Cortez, J., Knighton, B. G., Ledesma, D. A., Hudgens, C. W., Delcid, Y. F., Hu, Q., Onana, C. Y. B., Carapeto, F. C. L., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-16889-3 · Cited by 2 · see citing works

Patterns of expression and prognostic implication of glycoprotein nonmetastatic protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients

Beitner, A., Abu-Abeid, A., Dayan, D., Gat, A., Miodovnik, M., Levy, C., & Nizri‏, E. (2025) · Melanoma Research · doi:10.1097/cmr.0000000000001019 · Cited by 2 · see citing works

Anti‐PD ‐1 immunotherapy with adjuvant ablative fractional laser displays increased tumour clearance of squamous cell carcinoma, a murine study

Christensen, R. L., Wiinberg, M., Lerche, C. M., Demehri, S., Olesen, U. H., & Hædersdal, M. (2024) · Experimental Dermatology · doi:10.1111/exd.15013 · Cited by 2 · see citing works

Therapeutic Interruption of T Cell Development Generates High-Affinity T Cells That Escape Exhaustion and Improve Cancer ImmunotherapyPreprint

Dhuey, E., Oldridge, O., Ravishankar, R., Dada, H., Yu, Y., Anderson, M. S., & Minn, A. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.19.476935 · Cited by 2 · see citing works

mRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma

Feng, Y., Du, Y., Zhang, C.-T., Xie, F., & Yan, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189493 · Cited by 1 · see citing works

Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity

Wang, H., Meng, Q., Ito, Y., Kusumakar, K., & Mayadas, T. N. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0509 · Cited by 1 · see citing works

Paraneoplastic dermatoses in patients with hematologic malignancy

Singhaviranon, S., Klufas, T., & Aiudi, D. A. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.07.021 · Cited by 1 · see citing works

Adjuvant PD-1 Checkpoint Inhibition in Early Cutaneous Melanoma: Immunological Mode of Action and the Role of Ultraviolet Radiation

Brandlmaier, M., Hoellwerth, M., Koelblinger, P., Lang, R., & Harrer, A. (2024) · Cancers · doi:10.3390/cancers16081461 · Cited by 1 · see citing works

Proteogenomic Discovery of Neoantigens Facilitates Personalized Multi-antigen Targeted T cell Immunotherapy for Brain TumorsPreprint

Rivero-Hinojosa, S., Grant, M., Panigrahi, A. K., Zhang, H., Caisová, V., Bollard, C. M., & Rood, B. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.13.456263 · Cited by 1 · see citing works

Inhibition of Post-Surgery Tumour Recurrence via a Sprayable Chemoimmunotherapy Gel Releasing PD-L1 Antibody and Platelet-Derived ExosomesPreprint

Zhao, J., Ye, H., Qi, L., Wang, K., Chen, X., Song, J., Wang, H., Lu, Y., Cheng, M., He, Z., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1056003/v1

Lung injury induces a polarized immune response by self antigen-specific Foxp3 + regulatory T cellsPreprint

Shin, D. S., Ratnapriya, S., Cashin, C. N., Kuhn, L. F., Rahimi, R. A., Anthony, R. M., & Moon, J. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.09.527896

DCs targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumorsPreprint

López-Rodríguez, L., Morosi, L. G., Terza, F. L., Bourdely, P., Rospo, G., Amadio, R., Piperno, G. M., Russo, V., Volponi, C., Vodret, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.26.576259

Subunit-Selective PI3K Inhibition to Reverse Immunotherapy Resistance: Phase I/II Study of PI3Kβ and Pembrolizumab in Advanced Solid Tumors with PTEN LossPreprint

Tawbi, H. A., Burton, E. M., Dumbrava, E. E. I., Bohat, R., Milton, D. R., Amaria, R. N., McQuade, J. L., Glitza, I. C., Subudhi, S. K., Aparicio, A. M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4784661/v1

Intratumoral sustained release of resiquimod with ablative fractional laser induces efficacy in a cutaneous squamous cell carcinoma mouse model

Wiinberg, M., Melander, F., Lerche, C. M., Andresen, T. L., Olesen, U. H., & Hædersdal, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625867

Additional file 1 of Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs

Zhao, J., Ye, H., Lu, Q., Wang, K., Chen, X., Song, J., Wang, H., Lu, Y., Cheng, M., He, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19112622

Crossroads between autoimmunity and cancer: underlying mechanisms and clinical implications

Gjyrezi, A., Skarlis, C., Mavragani, C. P., & Giannakakou, P. (2025) · Physiological Reviews · doi:10.1152/physrev.00012.2025

The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice

Kang, J. M., Han, E. H., Choi, J.-K., Youm, S., Pareek, T. K., Levi, L., Kim, S., Letterio, J. J., & Lim, S. (2026) · Nature Communications · doi:10.1038/s41467-026-74891-3

In situ vaccination for the treatment of localized cancer and the prevention of metastatic disease

Lee, S., Kim, M., Wang, Y., Johnson, B., & You, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1862956

PD-L1 expression in germinal centers promotes humoral immunity by restricting T follicular regulatory cell differentiation

Akama‐Garren, E. H., Zhang, Y., Heesters, B. A., Fallon, P. G., & Carroll, M. C. (2026) · Immunity · doi:10.1016/j.immuni.2026.10.001

136 A novel combination therapy rescues response to checkpoint blockade in neoantigen-deficient cancers

Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. A., Freeman, G., Sharpe, A. H., Manstein, D., & Fisher, D. E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.02.150

Regulation of the Inflamed Tumor Phenotype in Melanoma Immunotherapy

Lo, J. A. (2016) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1 · see citing works

Abstract 2623: Identification of neo-antigens driving melanoma response to immune checkpoint blockers via in vivo screening

Day, C., Pérez‐Guijarro, E., Meskini, R. E., Ohler, Z. W., Lee, M. Y., Yang, H. H., Vodnala, S. K., Sharan, S. K., & Merlino, G. T. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2623

55P Mutations localized at the membrane predict immunotherapeutic efficacy in cancer treatment

Goldberger, Z., Hauert, S., Chang, K., Kurtanich, T. R., Alpar, A. T., Hubbell, J. A., & Briquez, P. S. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100160

Abstract 5720: Functional characterization of neoantigens determining immune checkpoint blockade response in mouse models of human melanoma

Pérez‐Guijarro, E., Day, C., Ohler, Z. W., Meskini, R. E., Yang, H. H., Vodnala, S. K., Graff‐Cherry, C., Chin, S., Fon, A., Michael, H., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5720